Real-time breath metabolomics to assess early response to CFTR modulators in adults with cystic fibrosis: an open-label proof-of-concept study
Emmanuelle Bardin(Centre National de la Recherche Scientifique), Stanislas Grassin‐Delyle(Inserm), Isabelle Sermet‐Gaudelus(Hôpital Necker-Enfants Malades), Hélène Salvator(Université Paris-Saclay), Philippe Devillier(Université Paris-Saclay), Camille Roquencourt(Hôpital Foch), Nicolas Hunzinger(Inserm), Dominique Grenet(Hôpital Foch), Elodie Lamy(Inserm), Sandra de Miranda(Hôpital Foch)
Cited by 1
Related Papers
<i>Pseudomonas aeruginosa</i>infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches
|Expert Review of Respiratory Medicine|2016|170
<i>Mycobacterium abscessus</i>and Children with Cystic Fibrosis
|Emerging infectious diseases|2003|159
Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis
|FEMS Microbiology Letters|2017|107
Modulators of CFTR. Updates on clinical development and future directions
|European Journal of Medicinal Chemistry|2021|67